Reviewing ProKidney (NASDAQ:PROK) & BioAtla (NASDAQ:BCAB)

BioAtla (NASDAQ:BCAB) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BioAtla and ProKidney, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	0	0	3	0	3.00
ProKidney	0	2	2	0	2.50

BioAtla currently has a consensus price target of $8.67, indicating a potential upside of 398.08%. ProKidney has a consensus price target of $4.50, indicating a potential upside of 88.28%. Given BioAtla’s stronger consensus rating and higher probable upside, research analysts clearly believe BioAtla is more favorable than ProKidney.

Profitability

This table compares BioAtla and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	-169.69%	-97.52%
ProKidney	N/A	N/A	-8.80%

Volatility and Risk

BioAtla has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Earnings and Valuation

This table compares BioAtla and ProKidney”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$250,000.00	334.89	-$123.46 million	($2.49)	-0.70
ProKidney	N/A	N/A	-$35.47 million	($0.57)	-4.19

ProKidney has lower revenue, but higher earnings than BioAtla. ProKidney is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

77.2% of BioAtla shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 11.5% of BioAtla shares are held by insiders. Comparatively, 41.5% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About BioAtla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.